Method and system for reducing the likelihood of a porphyromonas gingivalis infection in a human being

• US 10,583,033 B2
• Filed: 06/27/2018
• Issued: 03/10/2020
• Est. Priority Date: 02/04/2011
• Status: Active Grant

• Current Assignee: Seed Health, Inc.
• Original Assignee: Joseph E. Kovarik, Katherine Rose Kovarik
• Inventors: Kovarik, Katherine Rose, Kovarik, Joseph E.
• Primary Examiner(s): Lyons, Mary Maille
• Application Number:
  US16/020,433
• Publication Number:
  US 20180303658A1
• Time in Patent Office: 622 Days
• Field of Search: None
• CPC Class Codes: A61F 5/566 Intra-oral devices
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/519 ortho- or peri-condensed with heterocyclic rings
• CPC Class Codes: A61K 31/546 containing further heterocyclic rings, e.g. cephalothin
• CPC Class Codes: A61K 31/7052 having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61K 9/0063 Periodont
• CPC Class Codes: A61K 9/7007 Drug-containing films, membranes or sheets A61K9/0041, A61K9/0043, A61K9/006, A61K9/0063 take precedence

Abstract

A method and system of reducing the likelihood of an inflammatory disease developing by providing a mucosal adhesive strip to a subject, with the strip provided with at least one of a plurality of agents effective to hinder the growth of spirochetes bacteria in a subject'"'"'s oral cavity. In certain embodiments, an effective amount of Prevotella intermedia is provided to decrease the incidence of periodontitis and to reduce the progression of Alzheimer'"'"'s disease. In still other embodiments, the likelihood that a subject will suffer from Alzheimer'"'"'s disease is reduced by administering via local gingival application to a subject that has been diagnosed with periodontitis an effective amount of an antibiotic effective to kill spirochetes bacteria residing on the subgingival tooth area of the subject.

Claims

1. A method of reducing the likelihood of a Porphyromonas gingivalis infection in a human being comprising,

providing a bioadhesive strip to a human being who has been diagnosed with periodontitis, said strip binding to a mucosal membrane of said human being, the strip having a first and second side, the first side having a bioadhesive that binds to a mucosal membrane for at least 3 hours while inside a person'"'"'s mouth, wherein said strip comprises a therapeutically effective amount of an anti-biofilm agent, and a first antibiotic comprising methotrexate in an amount effective to inhibit collagenase activity, and compounds that facilitate the growth of desired bacteria beneficial to a person'"'"'s health;

and

orally administering to the subgingival tooth area of the human being a second antibiotic in an effective amount to kill Porphyromonas gingivalis bacteria residing on the subgingival tooth area of the human beings wherein said second antibiotic comprises one of azithromycin and ceftriaxone, and wherein the method reduces the likelihood of a Porphyromonas gingivalis infection in the human being, thereby also reducing the virulence factor gingipain.

2. The method as set forth in claim 1, wherein said strip comprises bioluminescent material.

3. The method as set forth in claim 1, wherein said strip is devoid of copper.

4. The method as set forth in claim 1, wherein said strip is devoid of manganese.

5. The method as set forth in claim 1, wherein said strip includes between 0.2 and 0.9% xylitol by weight.

11. The method as set forth in claim 1, wherein said strip has a surface topography for resisting bioadhesion and a pattern defined by a plurality of spaced apart features attached to or projected into a base surface, said plurality of features each having at least one microscale dimension and having at least one neighboring feature having a substantially different geometry, wherein an average spacing between adjacent ones of said features is between 0.5 and 5 microns.

12. The method as set forth in claim 1, wherein said strip includes at least about 200 mg xylitol.

13. The method as set forth in claim 1, further comprising orally administering to the subgingival tooth area of the human being an antibiotic in an effective amount to kill Porphyromonas gingivalis bacteria residing on the subgingival tooth area of the human being wherein said antibiotic comprises one of azithromycin and ceftriaxone.

14. The method as set forth in claim 1, further comprising administering Porphyromonas gingivalis modified to reduce the virulence factor gingipain by using a clustered regularly interspaced short palindromic repeats (CRISPR) and CRISPR associated (Cas) protein (CRISPR/Cas) system or a CRISPR/Cpf1 system.

6. A method of reducing the likelihood of a Porphyromonas gingivalis infection in a human being, comprising,

providing a bioadhesive strip to a human being who has been diagnosed with periodontitis, wherein said strip has a first and second side, the first side having a bioadhesive that is adapted to bind to a mucosal membrane for at least 1 hour while inside a person'"'"'s mouth, said strip being devoid of copper, wherein said strip includes at least about 200 mg xylitol and an effective amount of paquinimod to inhibit collagenase activity.

7. The method as set forth in claim 6, wherein said strip includes between 0.2 and 0.9% xylitol by weight.

8. The method as set forth in claim 6, wherein said strip comprises bioluminescent material.

9. The method as set forth in claim 6, wherein said strip has a surface topography for resisting bioadhesion and a pattern defined by a plurality of spaced apart features attached to or projected into a base surface, said plurality of features each having at least one microscale dimension and having at least one neighboring feature having a substantially different geometry, wherein an average spacing between adjacent ones of said features is between 0.5 and 5 microns.

10. The method of claim 6, wherein said strip is devoid of manganese.

15. The method as set forth in claim 6, further comprising administering Porphyromonas gingivalis modified to reduce the virulence factor gingipain by using a clustered regularly interspaced short palindromic repeats (CRISPR) and CRISPR associated (Cas) protein (CRISPR/Cas) system or a CRISPR/Cpf1 system.